Immunome, Inc. (NASDAQ:IMNM) CTO Purchases $198,030.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 21,000 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the purchase, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Immunome Stock Performance

Shares of IMNM stock opened at $13.47 on Thursday. The stock has a fifty day moving average price of $12.41 and a 200 day moving average price of $13.52. The stock has a market cap of $840.80 million, a PE ratio of -1.65 and a beta of 1.82. Immunome, Inc. has a 1 year low of $6.93 and a 1 year high of $30.96.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sofinnova Investments Inc. grew its stake in Immunome by 10.3% in the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after acquiring an additional 61,284 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Immunome in the first quarter valued at approximately $3,038,000. Victory Capital Management Inc. grew its position in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after purchasing an additional 1,194,451 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in shares of Immunome during the 2nd quarter worth approximately $1,379,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Finally, Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.